As the market opens for a new trading day, here are some stocks that are in focus. From BHEL’s new contract to Glenmark Pharma’s earnings update, several companies are in news today.
Here is a look at the list of stocks in news today, February 17.
Market recap
The Indian stock market ended last week on a weak note, marking its eighth straight session in the red. On Friday, the BSE Sensex fell 199.76 points to close at 75,939.21 after briefly plunging nearly 700 points during the day. The NSE Nifty 50 also slipped 102.15 points, settling at 22,929.25.
Stocks to watch on February 17, 2025 BHEL
The government-owned engineering company has won a huge Rs 6,700 crore contract from Singareni Collieries Company (SCCL) to build an 800 MW thermal power unit in Telangana. The project includes everything from design to final commissioning.
In the previous trading session, BHEL share price closed at Rs 192.93, down 4.40%.
MTNL
The state-run telecom company reported a net loss of Rs 836 crore in Q3FY25, almost the same as last year’s Rs 839 crore loss. Revenue dropped 11.6% to Rs 170 crore, highlighting ongoing challenges in the telecom sector.
MTNL share price closed at Rs 46.40 per share in the previous trading session, falling 6.26%.
ALSO READMcap of eight of top-10 valued firms tumbles Rs 2 lakh crore; Reliance biggest laggard Zen Technologies
The defence tech firm has invested in Vector Technics and Bhairav Robotics, expanding beyond combat training into advanced defence solutions. Zen Technologies’ share price dropped 7.26% on Monday, closing at Rs 1,345.40.
Zydus Lifesciences
The pharmaceutical company successfully completed a US FDA inspection at its Ambernath, Maharashtra, manufacturing facility with no issues found, a positive sign for regulatory compliance.
Zydus Lifesciences share price declined 4.62% to Rs 899.30 in the previous trading session.
Wipro
Wipro has appointed Amit Kumar as Managing Partner and Global Head of Wipro Consulting. He will report directly to CEO Srini Pallia and join the company’s Executive Board.
Alembic Pharma
Alembic Pharmaceuticals received a Voluntary Action Indicated (VAI) classification from the US FDA for its solid oral formulation facility in Jarod.
» Read More
